doc CURRICULUM VITAE

CURRICULUM VITAE   Author:Dr Ali Bazarbachi | Size:245.00 K | View:31 | Page:29

CURRICULUM VITAEAli A. Bazarbachi, M.D., Ph.D. Date of Birth:  January 25, 1965.Address:  Department of Internal Medicine  AmericanUniversity of Beirut  P.O.Box 113-6044  Beirut, LebanonTelephone:  (961)- 3-612434   Fax:(961)-1-34-5325E-mail:  bazarbac@aub.edu.lbNationalities...  
CURRICULUM VITAEAli A. Bazarbachi, M.D., Ph.D. Date of Birth:  January 25, 1965.Address:  Department of Internal Medicine  AmericanUniversity of Beirut  P.O.Box 113-6044  Beirut, LebanonTelephone:  (961)- 3-612434   Fax:(961)-1-34-5325E-mail:  bazarbac@aub.edu.lbNationalities:  French,LebaneseCurrent Position:  Professor of Medicine (Hematology and Oncology)  AssistantDean for Research, Faculty of Medicine  Director,Bone Marrow Transplantation Program  AmericanUniversity of Beirut, Beirut, LebanonEDUCATIONa- University degrees· Ph.D. Supervisor Degree (Habilitation à dirigerles recherches), University of Montpellier II, France,2000.· Ph.D. Degree (Doctorate of Science), University of Paris VII, France, 1995.· Diploma of Advanced Studies (DEA) University ofParis VII, France, 1991.· Master Degrees M.S. in Biology, Hematology,Genetics, Immunology, University of Saint-Etienne and University ClaudeBernard, Lyon France, 1989-1990.b- Medical school· French National Board of Hematology (DES), 1993.· French state MD (Doctorat d’état enMédecine), University of Paris VII, France 1993. (In the French system,this grade is obtained after Residency and Fellowship).· Medical School, University of Saint-Etienne,1982-1988c- Post-doctoral training· Residency in Internal Medicine, Fellowship in Hematology/Oncology: University of Paris VII(St-Louis Hospital, Henri Mondor Hospital, Curie Institute), Paris, France,1989-1993 (Combined program according to the French system).· Diploma of Clinical Oncology, Institut Gustave Roussy, University of Paris XI, 1992. HONORS· Rank 1 in the Lebanese Baccalaureate, Part I,Scientific section, 1981· Rank 4 in the French National Board Examination"Concours dinternat ", 1988· "Mention très honorable avec félicitations dujury", “Doctorat d’état en médecine”, 1993· "Mention très honorable avec félicitations dujury", Ph.D., 1995ACADEMIC POSITIONS· Assistant Dean for Research, Faculty of Medicine, American University of Beirut, 2006-Present.· Professor with long term contract, Department of Internal Medicine, American University ofBeirut, 2004-Present.· Director, Bone Marrow Transplantation Program, Department of Internal Medicine, American University ofBeirut, 2002-Present.· Associate Professor with long term contract, Internal Medicine, American University of Beirut, 2001-2004· Associate Professor, Internal Medicine, American University of Beirut,2000-2001.· Assistant Professor, Internal Medicine, American University of Beirut,1996-2000.· Faculty member  “Chef de Clinique”,University of Paris V, Medical school, 1993-1995.· Researcher, National Institute for MedicalResearch (INSERM), Paris, France, 1991-1992  RESEARCH AWARDS· Laureate of the French National Academy ofMedicine, (Prix Aimée et Raymond Mande), Paris, France, December 2008. · Hafez Kobeissi Award for Excellence inScientific Research, Lebanese National Research Council, Beirut, May 2002.· CEDRE Award (French-Lebanese IntergovernmentalResearch Program) for Excellence in Scientific Research, Beirut, June 2002.· Erwin Diwan Award, 10th InternationalConference on Human Retrovirology: HTLV and related viruses, Dublin, Ireland,June 2001.· French national prize for cancer research, (Prixdu Cher), 1996 MEMBERSHIP IN SCIENTIFIC AND MEDICAL SOCIETIES· The American Society of Hematology.· The European Hematology Association.· The French Order of Physicians.· The French Society of Hematology.· The European Blood and Marrow TransplantationGroup· The European Society for Medical Oncology· The International Retrovirology Association.· The Lebanese Order of Physicians· The Lebanese Cancer Society· The Lebanese Society of Hematology and bloodtransfusion· The Lebanese Society of Medical Oncologyuniversity COMMITTEES (AUB)· Member, Search committee for Vice President forMedical Affairs and Dean of the Faculty of Medicine, 2008-present.· Chairman, University Research Board,2007-present· Chairman, Research committee, 2006-present· Ex-officio, Academic committee, 2006-present· Ex-officio, Institutional Review Board,2006-present· Ex-officio, Institutional Animal Care andUtilization Committee, 2006-present· Faculty of Medicine representative, UniversityResearch Board, 2006-2007· Chairman, strategic planning subcommittee forresearch, Faculty of Medicine, August 2005-2007· Member, Tissue committee, Dec 2005-present· Member, Laboratory committee, Dec 2005-present· Member, Strategic planning committee, Faculty ofMedicine, April 2005-2007· Member, Strategic committee on graduateeducation and research, 2004-2005· Senate member, July 2003-2007.· Member, Organ transplant committee, April2004-present· Member, Task force on promotion, Sept 2001-Sept2002.· Member, Research Committee, Oct 2001-June 2003.· Member, MD-PhD Committee, 2003-present.· Member, Hospital committee on cancer,coordinator of the leukemia subcommittee, July 1997-present.· Member, Hospital safety Committee, July2000-June 2004.· Member, Scientific committee, Middle EastMedical Assembly  (MEMA), 1999, 2007.· Member, Task force on nosocomial infections,1999. PROFESSIONAL ORGANIZATIONS AND CONTINUOUS MEDICALEDUCATION · Chairman, Non Hodgkin Lymphoma Group, NationalComprehensive Cancer Network (NCCN), Middle East and North Africa project,December 2008-present.· President, The Lebanese Society of Hematologyand blood transfusion, 2007-present.· Vice-President, Lebanese Cancer Society, January2000-2008.· Chairman, Executive committee, second regionalmeeting, The Lebanese Society of Hematology and blood transfusion, Beirut,Lebanon, 2008.· Chairman, Scientific committee, first regionalmeeting, The Lebanese Society of Hematology and blood transfusion, Beirut,Lebanon, 2006.· Vice-President, The Lebanese Society ofHematology and blood transfusion, 2005-2007.· President and Chairman, Organizing committee,Seventh Middle East Oncology meeting, “COMO VII”. Beirut, Lebanon, 2005.· Chairman, Task force for medical and healthscience research, Lebanese National Research Council, Dec 2002-present· Chairman, Scientific committee, Middle EastOncology meeting, “COMO VI”. Beirut, 2003.· Chairman, Scientific committee, Middle EastOncology meeting, “COMO V”. Beirut, 2001.· Chairman, course on "High Dose Chemotherapyand Hematopoietic Stem Cell Transplantation". European School of Oncology,Beirut, Lebanon, 2000.· Chairman, course on "Supportive Care". European School of Oncology, Beirut, 1998. SCIENTIFIC AND MEDICAL JOURNALS  a- Editorial Board· Cancer Letter, Lebanon (1997-2002). · Hematology Oncology and Stem Cell Therapy,2008-present.· Iranian Journal of Basic Medical Sciences,2007-present· The Open Virology Journal, 2008- present· The Open Leukemia Journal, 2009-present b- Reviewer forinternational journals·  Blood· The Lancet Oncology· Oncogene· Leukemia· British Journal of Haematology· Leukemia & Lymphoma· J. Invest. Dermatol· FEBS letter· J.AIDS & Human Retroviruses· Haematologica· American Journal of Hematology· Lebanese Medical Journal. FUNDED RESEARCH GRANTS · 2009-2010: Specifictargeting of leukemia stem cells in HTLV-I associated adult T-cellleukemia/lymphomaLady TATA Memorial Trust (UK) (for a post-doctoral fellow)  GBP25 000 · 2007-2009: Designof new targeted therapies for HTLV-I associated adult T-cell leukemia/lymphomausing SCID mice infected with lymphoma spleen cells from mice transgenic forthe Tax gene of HTLV- ILebanese National Research Council  LBP30 000 000Lady TATA Memorial Trust (UK) (for a post-doctoral fellow)  GBP25 000 · 2007-2009: Molecularand cellular mechanisms of Tax-induced NF-kB activationAmerican University of Beirut- Medical Practice Plan:   $40 000American University ofBeirut- University Research Board:   $20 000 · 2007-2009: Proposalfor the development of bone marrow extracts(PI:Drs Ali Bazarbachi and MarwanEl-Sabban)MC2 company  $370 000 · 2007-2009: BionicMan: R&D Masterplan- In Situ Tissue Engineering(PI:Drs Ali Bazarbachi and MarwanEl-Sabban)Ossacur AG    $433 000 · 2005-2007: Roleof Tax ubiquitylation and sumoylation in NF-kB activation and proteasomedegradationAmerican University of Beirut- Medical Practice Plan:   $40 000AmericanUniversity of Beirut- University Research Board:   $20 000 · 2005-2007: BionicMan: R&D Masterplan- In Situ Tissue Engineering(PI:Drs Error! Contact not defined. and Marwan El-Sabban)OssacurAG    $228 000 · 2005-2006: PhaseII trial of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor,for patients with relapsed/refractory diffuse large cell lymphoma.NovartisOncology    $38 400 · 2005-2006: Anopen-label, multicenter, expanded access study of oral AMN107 in adult patientswith Imatinib (Glivec®/Gleevec®) - resistant or -intolerant chronic myeloid leukemia in blast crisis, accelerated phase orchronic phase. Co-investigatorNovartisOncology    $35 000 · 2005: Experimentalprotocol for testing AQIX® RS-I as an improved plasma substitute(PI: Drs Ali Bazarbachi and Marwan El-Sabban)Res-DelInternational Ltd  $9 000 · 2003-2006: Effectof arsenic trioxide on the gene expression profile and the p53 pathway inHTLV-I associated adult T-cell leukemia/lymphoma (ATL)Lebanese National Research Council  LBP15 000 000Lady TATA Memorial Trust (UK) (support for PhD student)  GBP18 000Lebanese National Research Council  LBP13 000 000 · 2003-2005: Effectof the proteasome inhibitor PS-341 on HTLV-I associated adult T-cellleukemia/lymphoma (ATL)American University of Beirut- Medical Practice Plan:     $30 000AmericanUniversity of Beirut- University Research Board:   $20 000Diana Tamari Sabbagh Research Fund:  $10 000 · 2002-2003: Mechanismsof NF-kB activation in HTLV-I associated adult T cell leukemia/lymphoma(ATL)Eli Lilly International Foundation(Germany):   Euros94 000 · 2001-2004: Themechanism of action and development of novel therapies for HTLV-I associatedadult T cell leukemia/lymphoma Eli LillyInternational Foundation (Germany):   Euros92 000Eli LillyInternational Foundation (Germany):   DM75 000American University of Beirut- Medical Practice Plan:   $25 000AmericanUniversity of Beirut- University Research Board:   $20 000DianaTamari Sabbagh Research Fund  $15 000French-Lebaneseintergovernmental Research fund (CEDRE)  LBP 6 600 000French-Lebanese intergovernmental Research fund (CEDRE)  FF130 000Cancer Research Association,France (ARC)  Euros40 000LebaneseNational Research Council:   LBP14 000 000 · 1998-2001: Themechanism of action of arsenic trioxide in combination with alpha interferon inHTLV-I transformed cellsTerry Fox Research Fund  $8 000French-Lebanese intergovernmental Research fund (CEDRE)   FF200 000Eli LillyInternational Foundation (Germany):   DM150 000American University of Beirut- Medical Practice Plan:   $20 000AmericanUniversity of Beirut- University Research Board:   $15 250MassabkiResearch Fund:  $8 000Lebanese National Research Council:   LBP20 000 000 · 1997-1998: Themechanism of action of alpha interferon in combination with zidovudine and/orarsenic in HTLV-I associated adult T-cell leukemia/lymphoma (ATL).American University of Beirut- Medical Practice Plan:     $24 000Lebanese National Research Council:   LBP5 000 000 · 1996-1997: Themechanism of action of zidovudine and alpha interferon in treating HTLV-Iassociated adult T-cell leukemia/lymphoma. AmericanUniversity of Beirut- University Research Board:   $ 4 000American University of Beirut- Medical Practice Plan:   $24 984 PUBLICATIONS AND COMMUNICATIONS   1- Original articles: 2009 Kchour G, Tarhini M, Kooshyar MM, El HajjH, Wattel E, Mahmoudi M, Hatoum H, Rahimi H, Maleki M,Rafatpanah H, Rezaee R, Tabatabaei Yazdi M, Shirdel A, de Thé H,Hermine O, Farid R, Bazarbachi A.Phase II study of the efficacy and safetyof the combination of arsenic trioxide, interferon alpha, and zidovudine innewly diagnosed chronic ATL.Blood. 2009;May 1. [Epub ahead of print] Bitar N, El Hajj H,Houmani Z, Sabbah A, Otrock Z, Mahfouz R, Zaatari G, Bazarbachi A.Adult T-cellLeukemia/Lymphoma in the Middle East: first report of two cases from Lebanon.Transfusion. 2009; in press. Tsukasaki K, Hermine O, BazarbachiA, Ratner L, Ramos JC, Harrington W Jr, OMahony D, Janik J, BittencourtAL, Taylor G, Yamaguchi K, Utsunomiya A, Tobinai K, Watanabe T.Definition, prognosticfactors, treatment, and response criteria of adult T-cell leukemia-lymphoma: aproposal from an international consensus meeting.J Clin Oncol. 2009;27:453-9. Mahfouz RA, Sabbagh AS, Shamseddine W, Bazarbachi A, Ibrahim G,Arayssi T, El Hajj N, Rayes R, Zaatari GS, Khazen G, Khalaf RA. Distribution of killer cell immunoglobulin-like receptor (KIR) genotypesin patients with familial Mediterranean fever.Genet Test Mol Biomarkers. 2009;13:91-5. Fathallah H, Taher A, Bazarbachi A, Atweh GF.Differences in response to fetal hemoglobin induction therapy inbeta-thalassemia and sickle cell disease.Blood Cells Mol Dis. 2009 Apr 3. 2008 Moarbess G, El-Hajj H,Kfoury Y, El-Sabban M, Lepelletier Y, Hermine O, Deleuze-Masquéfa C, Bonnet PAand Bazarbachi A.EAPB0203, a member of theimidazoquinoxaline family, inhibits growth and induces caspase dependent apoptosisin T cell lymphomas and HTLV-I associated adult T-cell leukemia/lymphoma.Blood 2008; 11: 3770-7. Epub 2008 Jan 24. Kfoury Y, Nasr R,Favre-Bonvin A, El-Sabban ME, Renault N, Giron ML, Setterblad N, ElHajj H, Chiari E, Mikati AG, Hermine O, Saib A, de Thé H, Pique C, and BazarbachiA.Ubiquitylated Taxtargets and binds the IKK signalosome at the centrosome.Oncogene 2008;27:1665-76. Epub 2007 Sep 24. Haddad L, El Hajj H, Abou-MerhiR, Kfoury Y, Mahieux R, El-Sabban M, Bazarbachi A.KSHV-transformed primary effusion lymphomacells induce a VEGF-dependent angiogenesis and establish functional gap junctionswith endothelial cells.Leukemia. 2008; 22:826-34. Epub 2007 Dec 20. Habib A, Hamade E, Mahfouz R, Nasrallah MS, de Thé H and Bazarbachi A. Arsenic Trioxide InhibitsATRA-Induced Prostaglandin E2 and Cyclooxygenase-1 in NB4 cells, aModel of Acute Promyelocytic Leukemia.Leukemia. 2008; 22:1125-30. Epub 2008 Mar 20. Callens C, Moura IC,Lepelletier Y, Coulon S, Renand A, Dussiot M, Ghez D, Benhamou M, Monteiro RC, BazarbachiA, Hermine O.Recent advances inadult T-cell leukemia therapy: focus on a new anti-transferrin receptormonoclonal antibody.Leukemia. 2008;22: 42-8. Epub 2007 Sep 27. Kfoury-Baz EM, Nassar RA,Tanios RF, Otrock ZK, Youssef AM, Albany C, Bazarbachi A, Salem ZM. Plasmapheresis inasparaginase-induced hypertriglyceridemia.Transfusion 2008;48:1227-30. Kchour G, Tarhini M,Sharifi N, Farid R, Khooei A, Shirdel A, Afshari J, Sadeghian A, Otrock ZK,Hermine O, El-Sabban M, Bazarbachi A. Increased microvesseldensity in involved organs from patients with HTLV-I associated adult T cellleukemia lymphoma. Leukemia and Lymphoma 2008; 49:265-70. Otrock ZK, Beydoun A, BaradaWM, Masroujeh R, Hourani R, Bazarbachi A. Transient global amnesiaassociated with the infusion of DMSO-cryopreservedautologous peripheral blood stem cells. Haematologica 2008; 93:e36-7. Katebi M, Sharifi N,Tarhini M, Otrock ZK, Bazarbachi A, Kchour G. Frequency of Epstein-Barrvirus expression in various histological subtypes of Hodgkins lymphoma. Histopathology  2008; 52:775-7. Otrock ZK, Hatoum HA, Salem ZM, Tawil A, Mahfouz RA, Zaatari GS, BazarbachiA.Long-term remission in a patient with hepatosplenic gammadelta T celllymphoma treated with bortezomib and high-dose CHOP-like chemotherapy followedby autologous peripheral stem cell transplantation.Ann Hematol.2008;87:1023-4. El Kinge A, Hatoum HA, Mahfouz RA, Otrock ZK, Jabbour E, Kantarjian H, BazarbachiA. Gemtuzumab Ozogamicin is a promising post-remission therapy for acutemyeloid leukemia.Leuk Res. 2008Jun 18. [Epub ahead of print]  Tarhini M, Kooshyar MM, Farzadnia M, Maleki M, Kchour G, Tabatabaee A,Otrock ZK, Bazarbachi A. Adult T cell leukemia-lymphoma with testicular involvement. Ann Hematol.2008 Oct 22. [Epub ahead of print]. Bazarbachi A,Hatoum H, Mugharbel A, Otrock Z, Yassine N, Muwakkit S, Salem Z, Shebbo W, JisrT, Abboud M, Ibrahim A.Hematopoietic stem cell transplantation in Lebanon: first comprehensivereport.Bone Marrow Transplant. 2008 Aug;42 Suppl 1:S96-S102. Itani WS, El-Banna SH, Hassan SB, Larsson RL, Bazarbachi A,Gali-Muhtasib HU.Anti colon cancer components from lebanese sage (Salvia libanotica)essential oil: Mechanistic basis.Cancer Biol Ther. 2008;7. [Epub ahead of print] Taher A, Shammaa D, Bazarbachi A, Itani D, Zaatari G, Greige L,Otrock Z, Mahfouz RA.Absence of JAK2 V617F mutation in thalassemia intermedia patients.Mol Biol Rep.2008 Sep 10. [Epub ahead of print] Otrock ZK, Taher AT, Shamseddeen WA, Zaatari G, Bazarbachi A,Mahfouz RA.Factor V HR2 haplotype: a risk factor for venous thromboembolism inindividuals with absence of Factor V Leiden.Ann Hematol.2008; 87:1013-6.  2007 El-Sabban ME,El-Khoury H, Hamdan-Khalil R, Sindet-Pedersen S, Bazarbachi A. Xenogenic bone matrixextracts induce osteoblastic differentiation of human bone marrow-derivedmesenchymal stem cells. Regen Med. 2007; 2:383-390. Abou-Merhi R, KhoriatyR, Arnoult D, El Hajj H, Dbouk H, Munier S, El-Sabban M, Hermine O, Gessain A,de Thé H, Mahieux R and Bazarbachi A. PS-341 or aCombination of Arsenic Trioxide and Interferon-a Inhibit Growth and Induce Caspase-Dependent Apoptosis inKSHV/HHV-8-Infected Primary effusion lymphoma cells. Leukemia.2007; 21:1792-801. Epub 2007 Jun 14.  Darwiche N, Abou-Lteif G, BazarbachiA.Reactive oxygen species mediateN-(4-hydroxyphenyl)retinamide-induced cell death in malignant T cells and areinhibited by the HTLV-I oncoprotein Tax.Leukemia. 2007; 21:261-9. Epub 2006 Nov 23.  Kchour G, Makhoul N, Mahmoudi M, KooshyarM, Shirdel A, Rastin M, Rafatpanah H, Tarhini M, Zalloua P, Hermine O, Farid R,Bazarbachi A.Zidovudineand interferon-a treatment induces a high response rate and reduces HTLV-1 proviralload and VEGF plasma levels in patients with adult T cell leukemia from NorthEast Iran.Leuk Lymphoma, 2007; 48:330-6.  Jamali FR, Otrock ZK,Soweid AM, Al-Awar GN, Mahfouz RA, Haidar GR, Bazarbachi A. An overview of thepathogenesis and natural history of post-transplant T-cell lymphoma.Leuk Lymphoma. 2007; 48: 1780-4. Rayes R, Bazarbachi A, Khazen G, Sabbagh A, Zaatari G,Mahfouz R. Natural Killer Cell Immunoglobulin-like Receptors (KIR) Genotypesin two Arab Populations: Will KIR become a genetic landmark between nations? Mol Biol Rep. 2007 Mar 26; [Epub ahead of print]  Dbaibo G, Kfoury Y, Darwiche N, PanjarianS, Kozhaya L, Nasr R, Abdallah M, Hermine O, El-Sabban M, de Thé H, BazarbachiA. Arsenic Trioxide Induces Accumulation ofCytotoxic Levels of Ceramide in Acute Promyelocytic Leukemia and Adult T-CellLeukemia/Lymphoma Cells Through de novo Ceramide Synthesis andInhibition of Glucosylceramide Synthase Activity. Haematologica, 2007; 92:753-62. 2006 Nasr R,Chiari E, El-Sabban M, Mahieux R, Kfoury Y, Abdulhay M, Yazbeck V, Hermine O,de The H, Pique C, Bazarbachi A. Tax ubiquitylation and sumoylation controlcritical cytoplasmic and nuclear steps of NF-kB activation.Blood. 2006; 107:4021-9. Epub 2006 Jan 19. Datta A, Bellon M,Sinha-Datta U, Bazarbachi A, Lepelletier Y, Canioni D, Waldmann TA,Hermine O, Nicot C. Persistent inhibitionof telomerase reprograms adult T-cell leukemia to p53-dependent senescence. Blood. 2006; 108:1021-9. Epub 2006 Mar 28. Mahfouz R, Rayes R,Mahfoud Z, Bazarbachi A, Zaatari G.Distribution of KillerCell Immunoglobulin-like Receptors (KIR) Genotypes in the Lebanese Population.Tissue Antigens. 2006; 68:66-71. Bashshur Z, Bazarbachi A, SchakalA, Haddad Z, El Haibi C, Noureddin B. IntravitrealBevacizumab for the Management of Choroidal Neovascularization in Age-relatedMacular Degeneration.Am J. Ophtalmol. 2006;142:1-9. Khoriaty R, Otrock ZK,Medawar WA, Khauli RB, Bazarbachi A. A case of successfuldouble sequential bone marrow and kidney transplantations in a patient withmultiple myeloma. Nephrol DialTransplant. 2006;21:3585-8. Epub 2006 Sep 12. Heraud  JM, Mortreux F, Merrien F,Contamin H, Mahieux R, Pouliquen JF, Wattel E, Gessain A, de Thé H, BazarbachiA. Hermine O, and Kazanji M. The efficacy of combined therapy ofarsenic trioxide and alpha interferon in human T-cell leukemia virustype-1-infected squirrel monkeys (Saimiri sciureus). Antiviral Res., 2006; 70:132-9. Epub 2006 Feb 28. 2005 Otrock ZK, MahfouzdRA, Oghlakian GO, Salem ZM, Bazarbachi A. Rituximab-inducedacute thrombocytopenia: a report of two cases. Haematologica, 2005 ; 90 Suppl: ECR23. Darwiche N, Abou-Lteif G, Najdi T, Kozhaya L,Abou Tayyoun A, Bazarbachi A, Dbaibo G. Human T-Cell Lymphotropic Virus TypeI-Transformed T Cells Have a Partial Defect in Ceramide Synthesis in Responseto N-(4-Hydroxyphenyl)Retinamide. Biochem. J. 2005; 392: 231-9. Kfoury Y, NasrR, Hermine O, De Thé H and Bazarbachi A.Pro-apoptotic regimes for HTLV-I transformed cells:targeting Tax and the NF-kB pathway.Cell Death and Differentiation, 2005; 12 Suppl 1:871-7. Nasr R,El-Sabban M, Karam J, Dbaibo G, Kfoury Y, Arnulf B, Lepelletier Y, Bex F, DeThé H, Hermine O, Bazarbachi A.Efficacy andmechanism of action of the proteasome inhibitor PS-341 in T cell lymphomas andHTLV-I associated adult T-cell leukemia/lymphoma.Oncogene, 2005; 24:419-30.  2004 Bazarbachi A, Ghez D,Lepelletier Y, Nasr R, De Thé H, El-Sabban M, Hermine O.Novel Therapeutic Approaches For Adult T Cell Leukemia.LancetOncology, 2004; 5:664-672. Bazarbachi A, Abou Merhi R, Gessain A, Talhouk R,El-Khoury H, Nasr R, Gout O, Sulahian R, Homaidan F, de Thé H, Hermine O, E.El-Sabban M. HTLV-I infected cells extravasate through theendothelial barrier using a local angiogenesis-like mechanism. CancerResearch 2004; 64:2039-46. Darwiche N, Hatoum A, Dbaibo G,Kadara H, Nasr R, Abou-Lteif G, Bazzi R, Hermine O, de Thé H, and BazarbachiA. N-(4-Hydroxyphenyl) Retinamide Induces GrowthArrest and Apoptosis in HTLV-I Transformed Cells. Leukemia2004;18:607-15. Moura IC, Lepelletier Y, Arnulf B, England P, Baude C, Beaumont C, BazarbachiA, Benhamou M, Monteiro RC and Hermine O.A neutralizing monoclonal antibody (mAb A24) directed against the transferrinreceptor induces apoptosis of tumor T lymphocytes from ATL patients.Blood 2004;103:1838-45. Hermine O, Dombret H,Poupon J, Arnulf B, Damaj G, Lefrere F, Rousselot P, Tibbi A, Solbes-LatouretteS, Fermand JP, Brouet JC, Laurent D, Varet B, de Thé H,Bazarbachi A. Phase II trial of arsenictrioxide (As2O3) and combination of alpha interferon (INF) and As2O3 inpatients with relapsed/refractory adult T cell leukemia (ATL).The Hematology Journal, 2004;5:130-4 Shamseddine A, Saliba T,Aoun E, Chahal A, El-Saghir N, Salem Z, Bazarbachi A, Khalil M, Taher A.Thrombotic thrombocytopenic purpura : 24 years of experience at theAmerican University of Beirut.J. Clin Apheresis, 2004; 19: 119-124 Abboushi N, El-Hed A,El-Assaad W, Kozhaya L, El-Sabban ME, Bazarbachi A, Badreddine R,Bielawska A, Usta J, Dbaibo GS.  Ceramide inhibits IL-2production by preventing protein kinase C-dependent NF-kappaB activation:possible role in protein kinase Ctheta regulation.J Immunol. 2004;173:3193-200.  Aouba A, Lambotte O,Vasiliu V, Divine M, Valensi F, Varet B, Bazarbachi A, Hermine O. Hemophagocyticsyndrome as a presenting sign of transformation of smoldering to acute adultT-cell leukemia/lymphoma: efficacy of anti-retroviral and interferon therapy.Am JHematol. 2004;76:187-9. 2003 Nasr R, Rosenwald A, El-Sabban ME, Arnulf B, Zalloua P, Lepelletier Y,Bex F, Hermine O, Staudt L, de Thé H, Bazarbachi A. Arsenic/Interferon specifically reverses two distinct gene networkscritical for the survival of HTLV-I infected leukemic cells.Blood 2003;101:4576-82. Haidar JH, Shamseddine A, Salem Z, Abou-Mrad Y, Nasr MR, Zaatari G, BazarbachiA. Loss of CD20 expression in relapsed lymphomas after rituximabtherapy.Eur.J.Haem. 2003;70:330-2. Haidar JH, Bazarbachi A, Nasr MR, El-Sabban ME, Daher R. Signet ring-like light chain myeloma with systemic spread.Eur.J.Haem. 2003,70:249-50. Taher A, Khalil I, Abou-Merhi R, Shamseddine A, Bazarbachi A.High prevalence of prothrombin G20210A mutation among patients withdeep venous thrombosis in Lebanon.Thrombosis and Haemostasis2003;89:945-6. (letter to the editor) Salem Z, Zalloua PA, Chehal A, Bitar N, Abboud M, KadriA, Chami B, Bazarbachi A.Effective treatment of hypereosinophilic syndrome with imatinibmesylate.The Hematology Journal, 2003; 4:410-412. Basbous J, Bazarbachi A, Granier C, Devaux C, Mesnard JM. The central region of HTLV-1 Tax protein contains distinct domainsinvolved in subunit dimerization. J. Virol. 2003; 77: 13028-35.  2002 El-SabbanM, Abu Merhi R, Abi Haidar H, Arnulf B, Khoury H, Basbous J, Nijmeh J, de ThéH, Hermine O And Bazarbachi A. HumanT-Cell Lymphotropic Virus Type I Transformed Cells Induce Angiogenesis andEstablish Functional Gap Junctions with Endothelial Cells.Blood 2002; 99: 3383-89. HaidarJ, Bazarbachi A, Mahfouz R, Abi Haidar H, Jaafar H, Daher R.SerumFlt-3 Ligand Variation as Predictive Indicator of Hematopoietic Stem CellMobilization.J Hematother Stem CellRes. 2002; 11:533-8. ChehalA, Sharara AI, Abi Haidar H, Haidar JH, Bazarbachi A. AcuteViral Hepatitis A and Parvovirus B19 Infections Complicated by Pure Red CellAplasia and Autoimmune Hemolytic Anemia. J Hepatology 2002; 37:163-165. (letterto the editor) Chehal A, Haidar J,Jabbour R, Yamout B, Bazarbachi A. Obstructive Sleep ApneaSecondary to Chronic Lymphocytic Leukemia. Annals of Oncology 2002; 13: 1833. (letter to the editor) Hermine O, Allard I, LevyV, Arnulf B, Gessain A, Bazarbachi A. A prospective phase II clinical trial with the use of zidovudine andinterferon-alpha in the acute and lymphoma forms of adult T-cellleukemia/lymphoma.The Hematology Journal 2002; 6: 276-282. Arnulf B, Villemain A, Nicot C, Mordelet E, Charneau P, Kersual J,Zermati Y, Mauviel A, Bazarbachi A, Hermine O. Human T cell lymphotropicvirus oncoprotein tax represses TGF-{beta}1 signaling in human T cells viac-Jun activation: a potential mechanism of HTLV-I leukemogenesis.Blood 2002; 100: 4129-4138.  2001 DarwicheN, El Sabban M, Bazi R, Nasr R, Hashimi S, Hermine O,de Thé H, Bazarbachi A.Retinoic Acid Dramatically Enhances the Arsenic Trioxide InducedCell Cycle Arrest and Apoptosis in Retinoic Acid Receptor a- Positive HumanT-Cell Lymphotropic Virus Type-I Transformed CellsThe Hematology Journal 2001; 2:127–135 Bazarbachi A, Hermine O.Treatment of adult T cellleukemia/lymphoma: current strategy and future perspectives.Virus Research 2001; 78:79-92.  Muwakkit S, Rachid R, BazarbachiA, Araysi T, Dbaibo G.Treatment resistantinfantile Evans syndrome.PediatricsInternational 2001; 43: 502-504. Taher A, Khalil I,Shamseddine A, El-Ahdab F, Bazarbachi A.Highprevalence of factor V Leiden mutation among healthy individuals and patientswith deep venous thrombosis in Lebanon: is Eastern Mediterranean region theprimary focus of this mutation?Thrombosis and Haemostasis, 2001;86:723-4. (letter to the editor)  2000 Bazarbachi A, Nasr R, El Sabban M,  Mahe A, Mahieux R, Gessain A, Darwiche N, Dbaibo G, Kersual J, Zermati Y, Dianoux L, Chelbi-Alix M, De The H,Hermine O. Evidence against a direct cytotoxic effect of alpha interferon andzidovudine in HTLV-I associated Adult T cell leukemia /Lymphoma.Leukemia 2000; 14: 716-721. Shamseddine A, Taher A,Jaafar H, Haidar J, Nasr R, Arzomian V, Salem Z, Bazarbachi A.Interferon alpha is aneffective therapy for congenital dyserythropoietic anaemia type I.Eur.J.Haem. 2000; 65: 207-209 Mansour A, Salti H, Han D,Khoury A, Friedman S, Salem Z, Ibrahim K, Bazarbachi A, Saghir N.Ocular findings inaplastic anemia.Ophtalmologica 2000; 214: 399-402. El Sabban M, Nasr R,Dbaibo G, Hermine O, Abboushi N, Quignon F, Ameisen JC, Bex F, de Thé H, BazarbachiA.Arsenic/Interferon-triggeredapoptosis in HTLV-I transformed cells is associated with Tax downregulation andreversal of NF-kB activation.Blood 2000, 96: 2849-2855.  1999 Bazarbachi A, El Sabban M, Nasr R, Quignon F, Awaraji C, Kersual J, Dianoux L,Haidar J, Hermine O, de Thé H.Arsenic trioxide andinterfero nalpha synergize to induce cell cycle arrest and apoptosis in HTLV-Itransformed cells. Blood 1999, 93: 278-283. 1998 Bazarbachi A, Muakkit S, Ayas M, Taher A, Salem Z, Solh H, Haidar J.Thiamine responsivemyelodysplasia. Br. J. Hematol. 1998, 102: 1098-1100. Hermine O, Wattel E,Gessain A, Bazarbachi A. Adult T Cell Leukemia: A review of established and new treatmentsBioDrugs, 1998, 10: 447-62.   1997 Bazarbachi A, Soriano V, Pawson R, Vallejo A, Moudgil T, Matutes E, .Peries J,Molina A,  de Thé H, Schulz TF, Catovsky D,  Gill PS.Mycosis Fungoides andSezary syndrome are not associated with HTLV-I infection: an internationalstudy. Br. J. Hematol. 1997, 98: 927-933. Bachmeyer C, BazarbachiA, Rio B, Delmer A, Hunault M, Zittoun R, Le Tourneau A, Aractingi S. Specific cutaneousinvolvement indicating relapse of Burkitts lymphoma.Am. J. Hematol. 1997; 54: 176. (letterto the editor).    1996 Levy V,  Rio B,Bazarbachi A, Hunault M, Delmer A, Zittoun R, Blanc V, Wolff M.  Two cases of epidemicmucomycosis infection in patients with acute lymphoblastic leukemia. Am. J. Hematol. 1996; 52: 64-65.  Bachmeyer C, Hunault M,Bazarbachi A, Hamant N, Aractingi S, Le Tourneau N, Marie JP, Diebold J,Zittoun R. Specific cutaneousinvolvement in B-cell prolymphocytic leukaemia. Br. J. Dermatol. 1996; 4: 979-980. (letter to the editor).  Rio B, Marjanovic Z,Belhocine R, Vekhoff A, Andrieu V, Klaren J, Boccaccio C, Delmer A, Hunault M, BazarbachiA, Levy V, Andreu G, Zittoun R. Difference in costs of autologoustransplants of peripheral and bone marrow hematopoietic stem cells. Aretrospective analysis over 1 year of transplantation in lymphomas, Hodgkinsdisease and myeloma Ann. Med. interne 1996; 147: 313-319 Bazarbachi A, Hermine O. Treatment by A combinationof zidovudine and alpha interferon in naive and pretreated Adult T-cellleukemia/ lymphoma patients. J. AIDS Hum.Retrovirology 1996; 13: s186-190. Levy V, Azoulay D, Rio B,Rabbat A, Hunault M, Bazarbachi A, Delmer A, Zittoun R.Successful treatment of severe hepaticveno-occlusive disease after allogenic bone marrow transplantation bytransjugular intrahepatic portosystemic stent shunt (TIPS)Bone Marrow Transplantation 1996; 18:443-445.  1995 Griscelli A, Gluckman E,Scrobohaci ML, Jonveaux P, Vu T, Bazarbachi A, Carosella ED, Sigaux F,Socie G.Aplastic anemia andparoxysmal nocturnal hemoglobinuria: search for a pathogenetic link. Blood 1995; 85: 1354-63. Bazarbachi A, Bachelez H, Dehen L, Delmer A, Zittoun R, Dubertret L. Lethalparaneoplastic pemphigus after Fludarabine treatment for chronic lymphocyticleukaemia. Ann. Oncol. 1995; 7: 731-732. (letter to the editor).  Hermine O, Bouscary D,Gessain A, Turlure P, Leblond V, Franck N, Buzyn-Veil A, Rio B, Macintyre E,Dreyfus F, Bazarbachi A. Treatment of HTLV-Iassociated adult T-cell leukemia-lymphoma with a combination of Zidovudine andAlpha-Interferon. N. Engl. J. Med. 1995; 332: 1749-1751. Bazarbachi  A, Huang M, Gessain A, Saal F, Saib A, Peries J, de Thé H, GalibertF.  HTLV-I complete proviralsequence from uncultured peripheral blood mononuclear cells derived from asubacute post-transfusional  spastic paraparesis. Int J. Cancer. 1995; 63: 1-6.  1994 Bazarbachi A, Saal F, Laroche L, Lasneret J,  Gessain A,  Daniel MT,Peries J.HTLV-I like particles andHTLVI related DNA sequences in an unambiguous case of sezary syndrome.  Leukemia 1994; 8: 201-207. Bazarbachi A,  Saal F, Lasneret J, Poirot Y, Bittoun P,  Hojman F,Peries J.Unintegrated HTLVI proviral  DNA  in cell lines and uncultured peripheral bloodmononuclear cells from tropical spastic paraparesis (TSP/HAM) and adult T-cellleukemia (ATL) patients . C.R.Acad. Sci. France, 1994, 317: 264-269. 1993 Bazarbachi A, Saal F, Laroche L, Flageul B, Peries J, de Thé H.HTLV-I provirus and MycosisFungoides. Science 1993;  259: 1470-1471. Daniel MT, Koken M, RomagneO, Barbey S, Bazarbachi A, Stadler M, Guillemin MC, Degos L, ChomienneC, de Thé H.PML protein expression inhematopoietic and acute promyelocytic leukemia cells. Blood 1993; 82: 1858-1867. Bazarbachi A, Scrobohaci ML, Gisselbrecht C, Marolleau JP, Mansi A, Brice P, HorraP, Drouet L. Changes in protein C,Factor VII and endothelial markers after Autologous Bone MarrowTransplantation: Endothelial lesions as predisposing  factors forvenoocclusive disease (VOD). Nouv. Rev. Fr. Hematol. 1993; 35: 135-143.   1990-1992 Morozov VA,  LagayeS, Saal F, Bazarbachi A,  Gout O, Lyon-Caen O, Peries J.High level of HTLVI specific protein expression and unusual proviral  integration in a patientwith ATL, chronic progressive myelopathy and Kaposis sarcoma. Leukemia 1992; 6: 746-750. Capesius C, Saal F, HojmanF, Bazarbachi A, Gessain A, Laroche L, Peries J.No evidence of HTLVImarkers in French patients with mycosis Fongoide and Sezary syndrome. Leukemia 1991; 5: 416-419. Hojman F, Bazarbachi A,Saal  F, Emanoil- Ravier R, Peries J.A novel electrophoreticstrategy allows detection of very low amount of retroviral circular DNA bypolymerase chain reaction. Meth.  Mol. Cell. Biol 1990; 2: 59-62. 2-Sollicited articles  Besson C, Arnulf B,Plumelle Y, Panelatti G, Bazarbachi A, Hermine O. Leucemie lymhomeHTLV-I : aspects cliniques. Presse Medicale, 2001; 30, 5: 239-242. Besson C, Arnulf B,Plumelle Y, Panelatti G, Bazarbachi A, Hermine O. Leucemie lymhomeHTLV-I : aspects thérapeutiques. Presse Medicale, 2001; 30, 5:243-245. Hermine O, de Thé H, Bazarbachi A. A potential role ofarsenic trioxide in the treatment of HTLV-1 virus associated T-cellLymphoproliferations. Hématologie, 1999; 5/1 suppl: 75-77. Bazarbachi A, Hermine O. Pathogenesis and new therapeutic approaches in HTLV-I associatedlymphoproliferative disorders. Hématologie 1996; 2: 312-320. Alexandre J, Levy V,Hunault M, Bazarbachi A, Delmer A, Rio B, Zittoun R. Bladder neoplasmsand cyclophosphamide. A propos of 3 cases and review of the literature. Bull.Cancer 1996; 83: 945-50. Bazarbachi A, Canivet M, Peries J. Rôle des rétrovirus dans la cancérogénèsehumaine. Bull. Cancer, 1995; 82: 85s-92s. Hunault M, Bazarbachi A,Zittoun R. Stratégie diagnostique dune hyperplaquettose isolée.  Lagazette médicale, 1995. Soussain C, Bazarbachi A.Leucémie/lymphome T de ladulte et virus HTLV-I. Hématoscopie, 1994, 1: 6-8. Bazarbachi A. Antibiotics and immunity. Pathol. Biol., 1990, 38, 949:952. Saal F, Gessain A, BazarbachiA, Gout O, Peries J. HTLVI Virus and associated pathologies. Retrovirus,1990, 6, 119:123. 3- Book chapters Bazarbachi A,  Raphael M, Gisselbrecht C, Hermine O.  Les lymphomes HTLV-1: Aspects anatomopathologiques, cliniques et thérapeutique.1997, pp 312-319. In Les lymphomes non Hodgkiniens (P. SolalCeligny, N. Brousse, Ch Fermé, C. Gisselbrecht, F. Reyes, F. Coiffier eds). Hermine O, Bazarbachi A.Lymphomagénèse virale : rôle du virus HTLVI. 1997, pp 72-78. In Leslymphomes non hodgkiniens (P. Solal Celigny, N. Brousse, Ch Fermé, C.Gisselbrecht, F. Reyes, F. Coiffier eds). Bazarbachi A, Gessain A. Human T-Cell Leukemia Virus Type I (HTLV-I) andTransplantation. 1996: 81-87. In Cancer inTransplantation: prevention and treatment. (J.L. Touraine et al. eds),   4-Invited lectures: Targeted therapy of adult T cellleukemia/lymphoma: From bench to bedside. Pan Arab Cancer Congress, Cairo,Egypt, 2009. Update on Myeloma and stem celltransplant. Middle East Medical Assembly, Beirut, Lebanon, 2009. Imatinib in CML blastcrisis. Dubai, 2008. Monitoring CML patientsduring imatinib therapy. Dasatinib Middle East Advisory Borad. Dubai, 2008. Multiple Myeloma, theLebanese Experience. Middle East Hematology Expert Meeting, Dubai,2008. State of the Artmanagement of diffuse large B cell lymphoma. Egyptian Hemato-Oncology GroupMeeting, Cairo, Egypt, 2008. Targeted therapy of AdultT-cell Leukemia: from bench to bedside. Department of Veterinary Biosciences atThe Ohio State University. Columbus, Ohio, USA, 2007 New Tyrosine Kinase Inhibitors. Iraqi Hematology Workshop, Amman, Jordan, 2007. Targeted therapy of AdultT-cell Leukemia: from bench to bedside. 19th Asian pacificCancer Conference. Tehran, Iran 2007. Targeted therapy of AdultT-cell Leukemia: from bench to bedside. “What have mousemodels taught us about cancer biology ?” LesTreilles Foundation, Tourtour, France, 2007.  Currenttreatment options for Imatinib resistant or intolerant CML patients. UAE hematology club meeting, Dubai, UAE, 2007 Current Management ofCML. BMS Special Workshop, Cairo, Egypt, 2007. Clinical Experiencewith Rituximab for the Treatment of B-Cell Malignancies and Disorders. MabtheraRegional launch Event , Dubai, UAE, 2006. New Tyrosine Kinase Inhibitors. IraqiHematology Workshop, Amman, Jordan, 2006. The Inhibitor ofVEGF-Receptors Tyrosine Kinase PTK-787/ZK222584 Blocks the Invasive Potentialof Adult T-Cell Leukemia Cells through the Endothelium. HTLV European Research Network, Verona, Italy, 2006. Tax ubiquitylation andsumoylation control critical cytoplasmic and nuclear steps of NF-kB activation. HTLV EuropeanResearch Network, Verona, Italy, 2006. Monitoring of CML, Resistance, Value ofFISH, QPCR, Mutation Analysis. Middle East Medical Assembly, Beirut,Lebanon, 2006. Targeted therapy of Adult T-cell Leukemia:from bench to bedside. Middle East Medical Assembly, Beirut, Lebanon, 2006. Ubiquitylation andsumoylation of the HTLV-I oncoprotein Tax control IKK binding and NF-kB activation. 12th International Conference onHuman Retrovirology. Montego Bay, Jamaica, 2005. Targeted therapy of AdultT-cell Leukemia. Iran National Oncology Meeting, Mashad, Iran, 2004. Targeted Therapy of AdultT-cell Leukemia: Arsenic Trioxide and Interferon Alpha Specifically Reverse TwoDistinct Gene Networks Critical For the Survival of HTLV-I Infected LeukemicCells. Third Workshop, Eli Lilly International Foundation. Hamburg, Germany.2004. Targeted therapy of AdultT-cell Leukemia. Oncology Research Seminar, Johns Hopkins Cancer Center, Baltimore,USA. 2004. Cancer cells extravasatethrough the endothelial barrier using a local angiogenesis-like mechanism:implications for invasion and metastasis. Joint US-NCI/Jordan Oncologysociety/King Hussein cancer center cancer conference. Amman, Jordan. 2004. Targeted Therapy of AdultT-cell Leukemia: Arsenic Trioxide and Interferon Alpha Specifically Reverse TwoDistinct Gene Networks Critical For the Survival of HTLV-I Infected LeukemicCells. Joint US-NCI/Jordan Oncology society/King Hussein cancer center cancerconference. Amman, Jordan. 2004.  Advances in lymphomatherapy. Special Saudi Arabia Oncology Workshop. Jeddah, SaudiArabia. 2003. Treatment of Adult T Cell Leukemia/Lymphoma: Current Strategy andFuture Perspectives. This lecture received the Erwin Diwan Award at the 10thInternational Conference on Human Retrovirology: HTLV and related viruses,Plenary session. Dublin, Ireland. 2001. Adult T cell Leukemia/Lymphoma: From HTLV-I pathogenesis toantiviral therapy. ASCO/ Pan Arab Lymphoma meeting. Cairo, Egypt. 2000. Arsenic/ interferon-a triggeredapoptosis in HTLV-I transformed cells is associated with Tax downregulation andreversal of NF-B activation. HTLV European Research Network. Generalmeeting.  Postdam, Germany. 2000. Arsenic Trioxide andInterferon alpha synergize to induce cell cycle arrest and apoptosis in HTLV-Itransformed cells. HTLV European Research Network, Paris, France. 1999. Effects of zidovudine andalpha-interferon on HTLV-I transformed cell lines and fresh ATL cells. HTLVEuropean Research Network, Munich, Germany. 1998. Antiviral treatment ofadult T cell  leukemia. HTLV European Research Network, Paris, France.1997. HTLV-I andtransplantation. International conference on transplantation and clinicalimmunology Lyon, France. 1995. Virus HTLV-I et pathologies associées. University of Nancy, Nancy,France. 1995. Treatment of HTLV-I associated adult T cell leukemia with acombination of zidovudine and alpha-interferon. HTLV European Research Network,London, UK. 1994. HTLVI like virus infection in sezary syndrome. European Organisationfor Research and Treatment of Cancer (cutaneous lymphoma project group) Paris,France. 1991. 5-Abstracts andpresentations: 2008 A. Bazarbachi, H. El-Khoury, R. Hamdan-Khalil, S. Sindet-Pedersen, M. E.El-Sabban. Xenogenic CartilageMatrix Extracts Specifically Induce Chondrocytic Differentiation of Human BoneMarrow Derived Mesenchymal Stem Cells. 13th Congressof the EuropeanHematology Association (EHA), Copenhagen,Denmark, June 12-15, 2008. Haematologica 2008;93(s1): 505.   A. Bazarbachi, L. Haddad, H. El Hajj, R. Abou-Merhi, Y. Kfoury, R. Mahieux, M.El-Sabban. KSHV Transformed Primary Effusion LymphomaCells Induce a VEGF dependent Angiogenesis and Establish Functional GapJunctions with Endothelial Cells. 13thCongress of the European Hematology Association (EHA),Copenhagen, Denmark, June 12-15, 2008. Haematologica 2008;93(s1): 420.   A. Bazarbachi, G. Moarbess, H. El-Hajj, Y. Kfoury, M. El-Sabban, Y. Lepelletier,O. Hermine, C. Deleuze-Masquéfa, P. Bonnet. EAPB0203, a member of theimidazoquinoxaline family, inhibits growth and induces caspase dependentapoptosis in T cell lymphomas and HTLV-I associated adult T-cellleukemia/lymphoma. 13th Congress of the European Hematology Association (EHA),Copenhagen, Denmark, June 12-15, 2008. Haematologica 2008;93(s1): 314.   A. Bazarbachi, O. Hermine, G. Panelatti, J.C. Ramos, P. Tortevoye, Z. Otrock, G.Taylor, A. Gessain, W. Harrington, Y. Plumelle. A worldwide meta-analysis onthe use of zidovudine and interferon-alpha for the treatment of adult T-cellleukemia/lymphoma. 13th Congress of the European HematologyAssociation (EHA), Copenhagen, Denmark, June 12-15, 2008. Haematologica2008; 93(s1): 311.   A. Bazarbachi, H. El Hajj,H. Hasegawa, M. El-Sabban, G. Zaatari, S. Saab, R. Mahfouz, R. Nasr, Y. Kfoury,O. Hermine, H. de Thé, W. Hall. Targeted therapy with arsenic trioxide andinterferon alpha eradicates leukemic cells in SCID mice model of adult T-cellleukemia/lymphoma. 13th Congress of the European Hematology Association (EHA),Copenhagen, Denmark, June 12-15, 2008. Haematologica 2008;93(s1): 117.   A. Bazarbachi, A. Habib,  E. Hamade,  R. Mahfouz, M. Nasrallah, H. DeThé. Arsenic Trioxide Inhibits ATRA-Induced Prostaglandin E2 andCyclooxygenase-1 in NB4 cells, a Model of Acute Promyelocytic Leukemia. 13thCongress of the European Hematology Association (EHA), Copenhagen, Denmark, June 12-15,2008. Haematologica 2008; 93(s1): 451.   Z. Otrock, R. Nassar, R. Mahfouz, K. Charafeddine, H. Hatoum, N.Kreidieh, E. Baz, A. Bazarbachi. Factors influencing engraftment inautologous peripheral stem cell transplantation: the experience of a tertiarycare center. 34th Annual Meeting of the EuropeanGroup for Blood and Marrow Transplantation, Florence, Italy, March 30-April 2, 2008. Bone Marrow Transplantation 2008; 41(S1): 429.   Hiba El Hajj, Hideki Hasegawa,Marwan El-Sabban, Ghazi Zaatari, Shehrazad Saab, Rami Mahfouz, Rihab Nasr,Youmna Kfoury, Olivier Hermine, Hugues de Thé, William Hall, Ali Bazarbachi. Targeted therapy with arsenic trioxide andinterferon alpha eradicates leukemic cells in SCID mice model of adult T-cellleukemia/lymphoma. HTLV European Research Network. General meeting. Brugges, Belgium, 2008.  Ali Bazarbachi, Gérard Panelatti, Juan CarlosRamos, Patricia Tortevoye, Zaher Otrock, Graham Taylor, Antoine Gessain,William Harrington, Yves Plumelle, Olivier Hermine. A worldwide meta-analysison the use of zidovudine and interferon-alpha for the treatment of adult T-cellleukemia/lymphoma. HTLV European Research Network. General meeting.  Brugges, Belgium, 2008.   2007 Hiba El Hajj, Hideki Hasegawa, Marwan El-Sabban, Ghazi Zaatari,Shehrazad Saab, Rami Mahfouz, Rihab Nasr, Youmna Kfoury, Olivier Hermine,Hugues de Thé, William Hall, AliBazarbachi. Targeted therapy with arsenic trioxide and interferonalpha eradicates leukemic cells in SCID mice model of adult T-cellleukemia/lymphoma. AmericanSociety of Hematology, Atlanta, Georgia, USA, 2007. Blood, 2007; 110:414a-415a.  AliBazarbachi,Gérard Panelatti, Juan Carlos Ramos, Patricia Tortevoye, Zaher Otrock, GrahamTaylor, Antoine Gessain, William Harrington, Yves Plumelle, Olivier Hermine. Aworldwide meta-analysis on the use of zidovudine and interferon-alpha for thetreatment of adult T-cell leukemia/lymphoma. American Society of Hematology,Atlanta, Georgia, USA, 2007. Blood, 2007; 110: 610a-611a.  Youmna Kfoury, Rihab Nasr, Arnaud Favre-Bonvin, Marwan El-Sabban,Noemie Renault, Marie-Louise Giron, Hiba El Hajj, Estelle Chiari, Abdul GhaniMikati, Olivier Hermine, Ali Saib, Hugues de Thé, Claudine Pique, Ali Bazarbachi.Molecular mechanisms of NF-kB activation by the HTLV-I oncoprotein Tax: role ofpost translational protein modification. American Society of Hematology,Atlanta, Georgia, USA, 2007. Blood,2007; 110: 108B. Z.Otrock, G. Zaatari, A. Taher, A. Shamseddeen, A. Sabbagh, I. Khalil, A.Bazarbachi, R. Mahfouz. Factor V HR2 haplotype: a risk factor for venousthromboembolism in individuals with absence of factor V Leiden. 12thCongress of the European Hematology Association (EHA), Vienna, Austria,June 7-10, 2007. Haematologica 2007; 92(s1): 309-10.  Y. Kfoury, R. Nasr, A.Favre-Bonvin, M. El-Sabban, N. Renault, M. Giron, H. El Hajj, E. Chiari, A.Mikati, O. Hermine, A. Saib, H. de Thé, C. Pique, A. Bazarbachi. Post translationalTax modifications control critical cytoplasmic and nuclear steps of NF-kB activation: Ubiquitylated Tax activates IKK on a centrosome-associatedIKK signalosome and sumoylated Tax mediates the formation of RelA-enriched Taxnuclear bodies and transcriptional activation. 12th Congress ofthe European Hematology Association (EHA), Vienna, Austria, June 7-10,2007. Haematologica 2007; 92(s1): 52.  G.Dbaibo, Y. Kfoury, N. Darwiche, S. Panjarian, L. Kozhaya, R. Nasr, M. Abdallah,O. Hermine, M. El-Sabban,  H. de Thé, A. Bazarbachi. Arsenic Trioxide Induces Accumulation of Cytotoxic Levelsof Ceramide in Acute Promyelocytic Leukemia and Adult T-Cell Leukemia/LymphomaCells Through de novo Ceramide Synthesis and Inhibition ofGlucosylceramide Synthase Activity. 12th Congress of the EuropeanHematology Association (EHA), Vienna, Austria, June 7-10, 2007. Haematologica 2007; 92(s1): 53.  N. Darwiche, G. Abou-Lteif, O.Hermine, H. de Thé, A. Bazarbachi. Reactive Oxygen Species Mediate N-(4-hydroxyphenyl)Retinamide-Induced Cell Death in Malignant T Cells and are Inhibited by theHTLV-I Oncoprotein Tax. 12th Congress of the European HematologyAssociation (EHA), Vienna, Austria, June 7-10, 2007. Haematologica2007; 92(s1): 273-274.  A.Bazarbachi, R. Nasr, M. El-Sabban, H. El Hajj, Y. Kfoury, L. Haddad,H. Hasegawa, W. Hall, H. de Thé, O. Hermine. Targeted therapy of adult T cell leukemia: from the benchto bedside. 12thCongress of the European Hematology Association (EHA),Vienna, Austria, June 7-10, 2007. Haematologica 2007; 92(s1): 112.  Hiba El Hajj, Marwan El-Sabban,Hideki Hasegawa, Rihab Nasr, Youmna Kfoury, Lara Haddad, Olivier Hermine,Hugues de Thé, William Hall, Ali Bazarbachi. Design of new targeted therapies forHTLV-I associated adult T-cell leukemia/lymphoma using SCID mice injected withlymphoma spleen cells from mice transgenic for the Tax gene of HTLV- I. 13th International Conference on HumanRetrovirology.Hakone, Japan, 2007. Aids. Res. Hum. Retrovirus. 2007, 23: 597.  Olivier Hermine, GérardPanelatti, Juan Carlos Ramos, Patricia Tortevoye, Graham Taylor, AntoineGessain, William Harrington, Yves Plumelle, AliBazarbachi. A worldwide meta-analysison the use of zidovudine and interferon-alpha for the treatment of adult T-cellleukemia/lymphoma.13th InternationalConference on Human Retrovirology. Hakone, Japan, 2007. Aids. Res.Hum. Retrovirus. 2007, 23:597-98.  Y. Kfoury, R. Nasr, A. Favre-Bonvin, M. El-Sabban, N. Renault, M.Giron, H. El Hajj, E. Chiari, A. Mikati, O. Hermine, A. Saib, H. de Thé, C.Pique, A. Bazarbachi.Ubiquitylated Tax activates IKK on a centrosome-associated IKK signalosome. 13th International Conference onHuman Retrovirology. Hakone, Japan, 2007. AhmadIbrahim, Zaher Otrock, A Mugharbel, R Mahfouz, Z Salem, W Shebbo, H Hatoum, GNsouli, A Shamseddine, R Jalloul, A Taher, N El-Saghir, E Baz, J Makarem, AEl-Kinge, N Droubi, N Kreidieh, N Yassine, T Jisr, Ali Bazarbachi,Autologous haematopoietic stem cell transplantation as an up-front therapy instage III multiple myeloma: the Lebanese experience.  33nd AnnualMeeting of the European Group for Blood and Marrow Transplantation (EBMT),Lyon, France, March 2007. Bone Marrow Transplantation. 2007; 39: S159. ZaherOtrock, H Hatoum, Z Salem, A Tawil, G Zaatari, Ali Bazarbachi. Long termremission in a patient with refractory hepatosplenic gamma-delta T-celllymphoma treated with bortezomib and high-dose CHOP-like chemotherapy followedby autologous peripheral stem cell transplantation. 33nd Annual Meeting ofthe European Group for Blood and Marrow Transplantation (EBMT), Lyon,France, March 2007. Bone Marrow Transplantation. 2007; 39: S151. 2006 HassanaFathallah, Ali Taher, Ali Bazarbachi, George F Atweh. Differences infetal hemoglobin induction in sickle cell disease and beta-thalassemia. American Society of Hematology,Orlando, USA, 2006. Blood, 2006; 108: 167a. HassanaFathallah, Ali Taher, Ali Bazarbachi, George F Atweh.  Additiveeffect of butyrate and hemin on fetal hemoglobin induction in erythroid cellsfrom sickle cell disease and beta-thalassemia.American Society of Hematology, Orlando, USA, 2006.Blood, 2006; 108: 360a. Ali Bazarbachi. Targeted therapy of adult T cell leukemia:from the bench to bedside. The 11th International Conference onDifferentiation Therapy and Innovative Therapeutics in Oncology,Versailles, France, 2006. Asma Arabi, Ali Bazarbachi, Lea Dib, Jawad Makarem, HassanHatoum, Abed El Rahman Kanj and Ghada El-Hajj Fuleihan. Prevention of post-bone marrow transplantationbone loss with zoledronate. 8th workshop on bisphosphonates, Davos,Switzerland, 2006. Bone, 2006; 38, Suppl 1:S66.  AliBazarbachi, Mohamad El Sayyad,Elizabeth Kfoury-Baz. Successful treatment with Rituximab of pure red cellaplasia in allogeneic bone marrow transplant with major ABO mismatch. 32ndAnnual Meeting of the European Group for Blood and Marrow Transplantation(EBMT), Hamburg, Germany, March 2006. Bone Marrow Transplantation.2006; 37: S69. 2005 Rihab Nasr, EstelleChiari, Marwan El-Sabban, Youmna Kfoury, Renaud Mahieux, Mohammad MaherAbdulhay, Victor Yazbeck, Olivier Hermine, Hugues de Thé, Claudine Pique, Ali Bazarbachi. Ubiquitylation andsumoylation of the HTLV-I oncoprotein Tax control IKK binding and NF-kB activation. 12th International Conferenceon Human Retrovirology. Montego Bay, Jamaica, 2005. Aids. Res. Hum. Retrovirus. 2005, 21:444.  Rami Mahfouz, Roni Rayes,Mona Ghasham, Rana Kalmoni, Ghazi Zaatari, Ali Bazarbachi. Distributionof Natural killer cell, immunoglobulin-like receptors (KIR) in the Lebanesepopulation. 31st Annual meeting of the American Society forHistocompatibility and Immunogenetics. Washington DC 2005. HumanImmunology 2005, 66: S25. Ali Bazarbachi and Olivier Hermine. Novel Therapeutic Approaches For Adult T CellLeukemia. 12thInternational Conference on Human Retrovirology.Montego Bay, Jamaica, 2005. Aids. Res. Hum.Retrovirus. 2005, 21: 445. Marwan El-Sabban, Lara Haddad, HildaKhoury, Youmna Kfoury, Roa Harb, Lamia Atweh, Hugues de Thé, Olivier Hermine, AliBazarbachi. The inhibitor of VEGF-receptors tyrosine kinase PTK-787 blocksthe invasive potential of adult T-cell leukemia cells through the endothelium. 12th International Conference on Human Retrovirology. Montego Bay, Jamaica, 2005. Aids. Res.Hum. Retrovirus. 2005, 21: 504.  2004 Bazarbachi Ali, Roa Harb, Hilda Khoury, Lara Haddad, Youmna Kfoury, LamiaAtweh, Eva Hamadeh, Olivier Hermine, Hugues de Thé, Marwan El-Sabban. The inhibitorof VEGF-receptors tyrosine kinase PTK-787 blocks the invasive potential ofadult T-cell leukemia cells through the endothelium. American Society ofHematology, San Diego, USA, 2004. Blood, 2004; 104: 28a. Bazarbachi Ali. Targeted therapy of Adult T-cell Leukemia. Oncology ResearchSeminar, Johns Hopkins Cancer Center. Baltimore, USA. 2004. Bazarbachi Ali, Rihab Nasr, Marwan El-Sabban, Andreas Rosenwald, GhassanDbaibo, Olivier Hermine, Louis Staudt, and Hugues de Thé. Targeted Therapy of Adult T-cell Leukemia: Arsenic Trioxide andInterferon Alpha Specifically Reverse Two Distinct Gene Networks Critical Forthe Survival of HTLV-I Infected Leukemic Cells. Third Workshop, Eli LillyInternational Foundation. Hamburg, Germany. 2004. Rihab Nasr, Andreas Rosenwald, Marwan E.El-Sabban, Bertrand Arnulf, Yves Lepelletier, Olivier Hermine, Louis Staudt,Hugues de The and Ali Bazarbachi. TargetedTherapy of Adult T-cell Leukemia: Arsenic Trioxide and Interferon AlphaSpecifically Reverse Two Distinct Gene Networks Critical For the Survival ofHTLV-I Infected Leukemic Cells. The 10th International Conferenceon Differentiation Therapy: Molecular target-based treatment of human cancer.Shanghai, China, 2004. Bazarbachi Ali, Raghida Abou Merhi, Antoine Gessain, Hilda El-Khoury,Rihab Nasr, Fadia Homaidan, Hugues de The, Olivier Hermine, and Marwan E.El-Sabban. HTLV-I Infected Cells Extravasate Through The Endothelial BarrierUsing a Local Angiogenesis-Like Mechanism: Implications For Invasion andMetastasis. The 10th InternationalConference on Differentiation Therapy: Molecular target-based treatment ofhuman cancer. Shanghai, China, 2004. Rihab Nasr, Marwan E. El-Sabban, AndreasRosenwald, Ghassan Dbaibo, Olivier Hermine, Louis Staudt, Hugues de The and AliBazarbachi. Targeted Therapy of Adult T-cellLeukemia: Arsenic Trioxide and Interferon Alpha Specifically Reverse TwoDistinct Gene Networks Critical For the Survival of HTLV-I Infected LeukemicCells. Joint US-NCI/Jordan Oncology society/King Hussein cancer centercancer conference. Amman, Jordan. 2004. Bazarbachi Ali, Raghida Abou Merhi, Hilda El-Khoury, Rihab Nasr, FadiaHomaidan, Olivier Hermine, and Marwan E. El-Sabban. HTLV-I Infected CellsExtravasate Through The Endothelial Barrier Using a Local Angiogenesis-LikeMechanism: Implications For Invasion and Metastasis. Joint US-NCI/Jordan Oncology society/King Hussein cancer centercancer conference. Amman, Jordan. 2004.  2003 Bazarbachi A, Abou Merhi R, Gessain A, Khoury H, Nasr R, Gout O, Homaidan F, DeThé H, Hermine O, El-Sabban M. Human T-Cell Lymphotropic Virus Type ITransformed Cells Induce Angiogenesis and Establish Functional Gap Junctionswith Endothelial Cells. American Society of Hematology, San Diego, USA,2003. Blood, 2003, 102: 839a. Nasr R, Karam JA, El-Sabban M, Arnulf B, Lepelletier Y, Bex F, deThé H, Hermine O, Bazarbachi A. Efficacy of the proteasome inhibitorPS-341 (Velcade) in peripheral T cell lymphomas and HTLV-I associated adultT-cell leukemia/lymphoma. American Society of Hematology, San Diego,USA, 2003. Blood, 2003, 102: 903a. Bazarbachi A, Abou Merhi R, Gessain A,Khoury H, Talhouk R, Nasr R, Gout O, Sulaihan R, Homaidan F, de Thé H, HermineO, El-Sabban M. HTLV-I infected cells extravasate through the endothelialbarrier using a local angiogenesis-like mechanism: implications for invasionand metastasis. 8th Congress of the European Haematology Association.Lyon, France, 2003. The Haematology Journal. 2003, 4s2: 22-23. Nasr R, Rosenwald A, El-Sabban M, Arnulf B, Lepelletier Y, Bex F,Hermine O, Staudt L, De The H, Bazarbachi A. Arsenic/Interferonspecifically reverses two distinct gene networks critical for the survival ofHTLV-I infected leukemic cells. 8th Congress of the European HaematologyAssociation. Lyon, France, 2003. The Haematology Journal. 2003, 4s2:134-135. Salem Z, Zalloua PA, Chehal A, Bitar N, Abboud M, KadriA, Chami B, Bazarbachi A. Effective treatment ofhypereosinophilic syndrome with imatinib mesylate. 8th Congress of theEuropean Haematology Association. Lyon, France, 2003. The HaematologyJournal. 2003, 4s2: 170. Bazarbachi A, Abou Merhi R, Nasr R,Gessain A, Gout O, de Thé H, Hermine O, El-Sabban M. HTLV-I infected cellsextravasate through the endothelial barrier using a local angiogenesis-like mechanism:implications for invasion and metastasis. 11th InternationalConference on Human Retrovirology: HTLV and related viruses, San Francisco,USA, 2003. Aids. Res. Hum. Retrovirus. 2003, 19: S16. Nasr R, Rosenwald A, El-Sabban M, Hermine O, Bex F, Staudt L, de ThéH, Bazarbachi A. Arsenic/Interferon specifically reverses two distinctgene networks critical for the survival of HTLV-I infected leukemic cells. 11thInternational Conference on Human Retrovirology: HTLV and related viruses,San Francisco, USA, 2003 Aids. Res. Hum. Retrovirus. 2003, 19: S52. Lepelletier Y, Moura IC,Arnulf B, England P, Beaumont C, Bazarbachi A, Bjorkman PJ, Monteiro R,Hermine O. A new neutralizing monoclonal antibody (MAB A24) directed againstthe transferring receptor inhibits the proliferation of T lymphocytes from ATLpatients. 11th International Conference on Human Retrovirology:HTLV and related viruses, San Francisco, USA, 2003. Aids. Res. Hum.Retrovirus. 2003, 19: S45. Bazarbachi A, Abou Merhi R, Gessain A, Khoury H, Nasr R, Gout O, Homaidan F, DeThé H, Hermine O, El-Sabban M. Human T-Cell Lymphotropic Virus Type ITransformed Cells Induce Angiogenesis and Establish Functional Gap Junctionswith Endothelial Cells. American Society of Hematology, San Diego, USA,2003. Blood, 2003, 102: 839a. Nasr R, Karam JA, El-Sabban M, Arnulf B,Lepelletier Y, Bex F, de Thé H, Hermine O, Bazarbachi A. Efficacy of theproteasome inhibitor PS-341 (Velcade) in peripheral T cell lymphomas and HTLV-Iassociated adult T-cell leukemia/lymphoma. American Society of Hematology,San Diego, USA, 2003. Blood, 2003, 102: 903a.  2002 Darwiche N, Hatoum A, NasrR, Abou-Lteif G, Bazarbachi A. N-(4-Hydroxyphenyl)retinamide (HPR) induces apoptosis and growth inhibition in malignant but not normal Tlymphocytes at clinically achievable concentrations. American Associationfor Cancer Research Special Meeting "Apoptosis and Cancer: BasicMechanisms and Therapeutic Opportunities in the Post-Genomic Era",Waikoloa, Hawaii, , 2002. Bazarbachi A, Abou Merhi R, Gessain A, Khoury H, Gout O, Abi Haidar H, De Thé H,Hermine O, And El-Sabban M. Human T-Cell Lymphotropic Virus Type I TransformedCells Induce Angiogenesis and Establish Functional Gap Junctions withEndothelial Cells. 7th Congress of the European Haematology Association.Florence Italy, 2002. The Haematology Journal. 2002, . Bazarbachi A, Nasr R, Rosenwald A, El-Sabban M, Merat R, Bex F, Hermine O, StaudtL, de Thé H. Arsenic Trioxide and Interferon Alpha Induce Proteasome-MediatedTax Degradation and Selectively Downregulate the Transcription of NF-kappaBTarget Genes in Human T Cell Lymphotropic Virus Transformed Cells. 7thCongress of the European Haematology Association. Florence Italy, 2002. TheHaematology Journal. 2002,  Nasr R, Rosenwald A,El-Sabban M, Bex F, Arnulf B, Hermine O, Staudt L, de Thé H, Bazarbachi A.Arsenic Trioxide and Interferon Alpha Induce Proteasome-Mediated TaxDegradation and Selectively Downregulate the Transcription of NF-kappaB TargetGenes in Human T Cell Lymphotropic Virus Transformed Cells. HTLV EuropeanResearch Network. General meeting.  Berlin, Germany, 2002. El-Sabban M, Abou Merhi R,Gessain A, Arnulf B, Khoury H, Gout O, Abi Haidar H, de Thé H, Hermine O, BazarbachiA. Human T-Cell Lymphotropic Virus Type I Transformed Cells InduceAngiogenesis and Establish Functional Gap Junctions with Endothelial Cells. HTLVEuropean Research Network. General meeting.  Berlin, Germany,2002.  Nasr R, Rosenwald A, El-Sabban M, Arnulf B, Lepelletier Y, Bex F,Hermine O, Staudt L, de Thé H, Bazarbachi A. Arsenic/Interferonspecifically reverses two distinct gene networks critical for the survival ofHTLV-I infected leukemic cells. American Society of Hematology,Philadelphia, USA, 2002. Blood 2002, 100: 215b. El-Sabban M, Abou Merhi R, Gessain A,Arnulf B, Khoury H, Gout O, Abi Haidar H, De Thé H, Hermine O, Bazarbachi A.Human T-Cell Lymphotropic Virus Type I Transformed Cells InduceAngiogenesis and Establish Functional Gap Junctions with Endothelial Cells. AmericanSociety of Hematology, Philadelphia, USA, 2002. Blood, 2002, 100:727a.  2001 Bazarbachi A, Hermine O. Treatment ofAdult T Cell Leukemia/Lymphoma: Current Strategy and Future Perspectives. 10thInternational Conference on Human Retrovirology: HTLV and related viruses,Dublin, Ireland, 2001. Aids. Res. Hum. Retrovirus. 2001, 17: S28. Nasr R, El Sabban M,Basbous J, Abou-Merhi R, Bex F, Hermine O, de Thé H, Bazarbachi A. Arsenic/Interferon-triggeredapoptosis in HTLV-I transformed cells is associated with proteasome mediatedTax degradation and reversal of NFB activation. 10thInternational Conference on Human Retrovirology: HTLV and related viruses,Dublin, Ireland, 2001. Aids. Res. Hum. Retrovirus. 2001, 17: S50. Nasr R, Darwiche N, de Thé H, Bazarbachi A. Retinoicacid increases retinoid X receptor DNA binding activity despite the degradationof retinoid receptor proteins in HTLV-I transformed cells. 10thInternational Conference on Human Retrovirology: HTLV and related viruses,Dublin, Ireland, 2001. Aids. Res. Hum. Retrovirus. 2001, 17: S55. El Sabban M, Abou-Merhi R, Abi-Haidar H, Arnulf B, Basbous J, KhouryH, Nijmeh J, Hermine O, Bazarbachi A. Human T-Cell Lymphotropic VirusType I Transformed Cells Induce Angiogenesis and Communicate with EndothelialCells Through Gap Junctions. 10th International Conference onHuman Retrovirology: HTLV and related viruses, Dublin, Ireland, 2001.  Hermine O, Bazarbachi A. Treatment of Adult T CellLeukemia/Lymphoma: Clinical results of new therapeutic approaches. 10thInternational Conference on Human Retrovirology: HTLV and related viruses,Dublin, Ireland, 2001. Aids. Res. Hum. Retrovirus. 2001, 17: S28. Arnulf B, Villemain A, Nicot C, Charneau P, Kersual J, Zermati Y,Derkinderen M, Bex F, Bazarbachi A, Hermine O. Human T cell lymphotropic virusoncoprotein Tax represses TGF-b1 signaling in human T-cells via c-junactivation: A potential mechanism of HTLV-I leukemogenesis. 10thInternational Conference on Human Retrovirology: HTLV and related viruses,Dublin, Ireland, 2001. Aids. Res. Hum. Retrovirus. 2001, 17: S24. Bazarbachi A, Nasr R, El Sabban M, Hermine O, de Thé H. Arsenic/Interferon-a triggeredapoptosis in HTLV-I transformed cells is associated with proteasome mediatedTax degradation and reversal of NF-kB activation. Joint International Congresson APL and Differentiation Therapy, Rome, Italy, 2001.  2000 Darwiche N, El-Sabban M, BazziR, Nasr R, deThé H, Bazarbachi A. Retinoic acid dramatically enhancesthe arsenic trioxide induced cell cycle arrest and apoptosis in retinoic acidreceptor-a positive Human T-cell leukemia virus type-I transformedcells.  Cell and Molecular Biology Keystone Symposium: Cancer, CellCycle and Therapeutics. Steamboat Springs, CO, 2000 p.63. Arnulf B, Oddos J, ZermatiY, Kersual J, Bazarbachi A, Hermine O. Etude du rôle de la protéinevirale oncogénique TAX sur les signaux de transduction du TGF-b. FrenchSociety of  Hematology, Paris, France 2000. Bazarbachi A, Fadel E, Jaafar H, Mahfouz R, Haidar J, Jalloul R, Jisr T, IbrahimA. Cryopreservation of hematopoietic stem cells is not required for autologousperipheral stem cell transplantation in patients with multiple myeloma. Europeanbone marrow transplantation group, Innsbruck, Austria 2000. Ibrahim A, Haidar J, JisrT, Mahfouz R, Abs L, Jaafar H, Mugharbel A, Bazarbachi A Autologousnon-cryopreserved peripheral stem cell transplantation for malignantlymphomas  European bone marrow transplantation group, Innsbruck,Austria 2000. El Sabban M, Nasr R,Dbaibo G, Hermine O, Abboushi N, Bex F, De The H, Bazarbachi A. Arsenic/interferon-a triggered apoptosis in HTLV-I transformed cells is associated withTax downregulation and reversal of NF-kB activation. HTLV European ResearchNetwork. General meeting.  Postdam, Germany 2000. Bazarbachi A, Fadel E,Jaafar H, Mahfouz R, Haidar J, Jalloul R, Jisr T, Ibrahim A. Cryopreservationof hematopoietic stem cells is not required for autologous peripheral stem celltransplantation in patients with multiple myeloma. Middle East Society forOrgan Transplantation, Beirut, Lebanon 2000. Ibrahim A, Haidar J, JisrT, Mahfouz R, Abs L, Jaafar H, Mugharbel A, Bazarbachi A. Autologousnon-cryopreserved peripheral stem cell transplantation for malignant lymphomas MiddleEast Society for Organ Transplantation, Beirut, Lebanon 2000. Nasr R, El Sabban M, BasbousJ, Abou-Merhi R, Bex F, Hermine O, De The H, Bazarbachi A. Arsenic/Interferon-triggeredapoptosis in HTLV-I transformed cells is associated with proteasome mediatedTax degradation and reversal of NF-kB activation. American Society ofHematology, San Francisco, USA, 2000. Blood, 2000, 96: 96a.  Basbous J, Abi-Haidar H,Nijmeh J, Abou-Merhi R, Hermine O, Bazarbachi A, El Sabban M. Adhesionand intercellular communication between HTLV-I transformed cells and otherneoplastic T-cell lymphocytes and vascular endothelium. American Society ofHematology, San Francisco, USA, 2000. Blood, 2000, 96: 125a.  Hermine O, Dombret H,Poupon J, Arnulf B, Damaj G, Lefrere F, Rousselot P, Tibbi A, Solbes-LatouretteS, Fermand JP, Brouet JC, Degos L, Varet B, de Thé H, BazarbachiA. Phase II trial of arsenic trioxide (As2O3) and combination of alphainterferon (INF) and As2O3 in patients with relapsed/refractory adult T cellleukemia (ATL). American Society of Hematology, San Francisco, USA,2000. Blood, 2000, 96: 342a.  DarwicheN, Sabban M, Bazzi R, Nasr R, Hermine O, de Thé H, BazarbachiA. Retinoic acid and arsenic trioxide combination induces cell cycle arrestand apoptosis and downregulates Tax in retinoic acid receptor –a positive HTLV-Itransformed cells. American Society ofHematology, San Francisco, USA, 2000. Blood, 2000, 96: 178b Nasr R, DarwicheN, De The H, Bazarbachi A. Retinoic acid increases retinoid Xreceptor DNA binding activity despite the degradation of retinoid receptorproteins in HTLV-I transformed cells. AmericanSociety of Hematology, San Francisco, USA, 2000. Blood, 2000, 96:183b 1999 Hermine O, Gessain A, BazarbachiA. Treatment of HTLV-I associated adult T-cell leukemia/lymphoma with acombination of zidovudine and alpha interferon. Report of the Frenchexperience. IX International conference on human retrovirology: HTLV. Kagoshima,Japan, 1999. J. AIDS Hum. Retrovirology 1999; 20: A7. El-Sabban M, Nasr R,Quignon F, Hermine O, deThé H, Bazarbachi A. Induction of cell cyclearrest and apoptosis in HTLV-I transformed cells by a combination of arsenictrioxide and interferon alpha. IX International conference on humanretrovirology: HTLV. Kagoshima, Japan, 1999. J. AIDS Hum. Retrovirology1999; 20: A29. El-Sabban M, Nasr R,Dbaibo G, Hermine O, Bex F, de Th´ H, Bazarbachi A. Arsenic trioxide andalpha interferon combination downregulates Tax and targets the NF-kB pathway inHTLV-I transformed cells. American Society of Hematology, New Orleans,USA, 1999. Blood, 1999, 92 (suppl 1). Bazarbachi A, Abdallah M, Nasr R, El-Assaad W, El-Sabban M, Dbaibo G. Involvementof the ceramide pathway in the cytotoxicity of arsenic trioxide and interferonalpha in HTLV-I transformed cells. American Society of Hematology, NewOrleans, USA, 1999. Blood, 1999, 92 (suppl 1). Bazarbachi A, Fadel E, Haidar J, Jaafar H, Mahfouz R, Jisr T, Ibrahim A. Stemcell cryopreservation is not required for single autologous peripheral stemcell transplantation in patients with multiple myeloma. American Society ofHematology, New Orleans, USA, 1999. Blood, 1999, 92 (suppl 1). Ibrahim A. Fadel E, JisrT, Mahfouz R, Jaafar H, Mokdad A, Haidar J, Bazarbachi A. Autotransplantationfor relapsed, refractory or high risk lymphoma with non cryopreservedhematopoietic peripheral stem cells. American Society of Hematology, NewOrleans, USA, 1999. Blood, 1999, 92 (suppl 1). El-Sabban M, Nasr R, Hermine O, de Thé H,Bazarbachi A. Induction of cell cycle arrest and apoptosis in HTLV1transformed cells by combination of arsenic trioxide and interferon-a. HTLVEuropean Research Network. Pathogenesis Workshop.  Paris,France 1999. Virus Research, 1999, 65, p 3. 1998 Bazarbachi A, El-Sabban M, Hermine O. Effects of Zidovudine and Interferon Alphaon HTLV-I transformed cell lines and fresh ATL cell. HTLV European ResearchNetwork. Pathogenesis Workshop. München,1998. Bazarbachi A, El Sabban M, Nasr R, Quignon F, Awaraji C, Kersual J, Dianoux L,Haidar J, Hermine O, de Thé H. Arsenic trioxide and interferon-a synergize toinduce cell cycle arrest and apoptosis in HTLV-I transformed cells. AmericanSociety of Hematology, Miami, USA, 1998. Blood, 1998, 92 (suppl 1):600a. Shamseddine A, Taher A,Haidar J, Nasr R, Salem Z, Saghir N, Shaib F, Bazarbachi A. Interferonalpha is an effective therapy for congenital dyserythropoietic anemia type I. AmericanSociety of Hematology, Miami, USA, 1998. Blood, 1998, 92 (suppl 1):23b. Haidar J, Daher R, MahfouzR, Bazarbachi A. Serum FLT-3 ligand: A predictive marker for neutropeniaduring the course of stem cell mobilization for autologous peripheral stem celltransplantation. American Society of Hematology, Miami, USA, 1998. Blood,1998, 92 (suppl 1): 122a Hourani M, Birjawi GH, Khoury N, BazarbachiA.Comparison of total body MRI and skeletal series in patients withmultiple myeloma. American Society of Hematology, Miami, USA, 1998. Blood,1998, 92 (suppl 1): 264b. 1997 Bazarbachi A, Gessain A, Hermine O. Treatment of HTLV-I associated adult T cellleukemia/lymphoma with a combination of zidovudine and interferon alpha.VIIIth International Conference in Human Retrovirology : HTLV. Rio DeJaneiro, Brazil. 1997 Hermine O, Gessain A, Bazarbachi A. Traitement des leucémiesT de l’adulte, associées au virus HTLVI (ATL) par une association de Zidovudine(AZT) et d’Interféron a. Groupe détude des lymphomes de ladulte, Deauville, France1997. Bazarbachi A, Nasr R, El-Sabban M, Awaraji C, Haidar J, Hermine O. Cell cycleeffects of zidovudine and interferon alpha on HTLV-I transformed cell lines andfresh ATL cells. American Society of Hematology, San Diego, USA, 1997. Blood,1997, 90 (suppl 1) : 201b. Bazarbachi A, Haidar J, Salem Z, Solh H, Ayas M. Thiamine responsivemyelodysplasia. American Society of Hematology, San Diego, USA, 1997. Blood,1997, 90 (suppl 1) : 284b. Hermine O, Gessain A, Bazarbachi A.Treatment of HTLV-I associated adult T cell leukemia/lymphoma with acombination of zidovudine and interferon alpha. American Society ofHematology, San Diego, USA, 1997. Blood, 1997, 90 (suppl 1) : 332a. 1996 Rio B, Marjanovic Z, LevyV, Hunault M, Bazarbachi A, Zittoun R. Vaccination for yellow feverafter bone marrow transplantation. European bone marrow transplantationgroup, Vienna, Austria 1996. Levy V, Rio B, Azoulay D, Hunault M, BazarbachiA, Delmer A, Zittoun R. Successfull treatment of severe venoocclusivedisease of the liver after allogenic BMT by transjugular intrahepaticportosystemic shunt (TIPS). European bone marrow transplantation group, Vienna,Austria 1996. 1995 Bazarbachi A, Bouscary D, Gessain A, Turlure P, Leblond V, Franck N, Buzyn-VeilA, Rio B, Macintyre E, Soussain C,  Gardin C, Bachelez H, Vernant JP,Dreyfus F, Hermine O. Treatment of HTLV-I associated adult T-cellleukemia-lymphoma with a combination of zidovudine and interferon alpha. VIIInternational conference on human retrovirology: HTLV. Paris, France 1995. J.AIDS Hum. Retrovirology 1995; 2: 284. Bazarbachi A, Huang M, Gessain A, Saal F, Saib A, Peries J, de Thé H, Galibert F. Human T-cell leukemia virus type I inpost-transfusional  spastic paraparesis: complete proviral sequence fromuncultured blood cells. VII International conference on human retrovirology:HTLV. Paris, France 1995. J. AIDS Hum. Retrovirology 1995; 2: 283 Bazarbachi A, Soriano V, Vallejo A, Moudgil T, Peries J,  de The H, Gill PS.Mycosis Fungoides and Sezary syndrome are not associated with HTLV-I infection:an international study. VII International conference on human retrovirology:HTLV. Paris, France 1995. J. AIDS Hum. Retrovirology 1995; 2: 237. Bachmeyer C, Hunault H, BazarbachiA, Hamant N, Aractingi S, Grateau G, Le Tourneau A, Marie JP, Diebold J,Zittoun R. Unusual cutaneous involvement indicating B prolymphocytic leukemia. 13thCongress of the European Association of Internal Medicine.  Athens,Greece, 1995. Eur. J. Intern. Med. 1995; 6: 15. Bachmeyer C, BazarbachiA, Hunault H, Aractingi S, Grateau G, Le Tourneau A, Diebold J, Zittoun R.Specific cutaneous involvement indicating Burkitts lymphoma relapse. 13thCongress of the European Association of Internal Medicine.  Athens,Greece 1995. Eur. J. Intern. Med. 1995; 6: 14. Bazarbachi A, Bachelez H, Dehen L, Delmer A, Rio B, Vekhoff A, Hunault M, Levy V,Zittoun R. Pemphigus paranéoplasique mortel après traitement par fludarabinedune leucémie lymphoide chronique. French Society of  Hematology,Paris, France 1995. Nouv. Rev. Fr. Hematol. 1995,1: 65 . Bazarbachi A, Saal F,  Peries J, de Thé H. Mycosis fungoide et syndrome desézary: absence de marqueurs dinfection par le virus HTLV-I. French Society of  Hematology,Paris, France 1995. Nouv. Rev. Fr. Hematol. 1995, 1: 98. Hermine O, Bouscary D,Gessain A, Turlure P, Leblond V, Franck N, Buzyn-Veil A, Rio B, Macintyre E,Deyfus F, Peries J, Bazarbachi A. Traitement deslymphoproliférations liées au virus HTLV-I par une combinaison dAZT etdinterféron alpha. French Society of  Hematology, Paris, France1995. Nouv. Rev. Fr. Hematol. 1995, 1: 68. Levy V, Hunault M, CoulonMA, Bazarbachi A, Delmer A, Rio B, Chevalier JP, Zittoun R. Leucémieaigue myéloide après transplantation cardiaque, à propos dun cas.  FrenchSociety of Hematology, Paris, France 1995.  Nouv. Rev. Fr. Hematol.1995, 1: 251. Levy V, Hunault M, BazarbachiA, Delmer A, Cymbalista F, Rio B, Zittoun R. Deux observations decarcinomes vésicaux après utilisation prolongée de Cyclophosphamide entraitement de maladie de Waldenstrom.  French Society of Hématology, Paris, France 1995. Nouv. Rev. Fr. Hematol. 1995, 1:169. Bazarbachi A, Bouscary D, Gessain A, Turlure P,  Leblond V, Franck N, Buzyn-Veil A, Rio B, Macintyre E, Soussain C, Gardin C, Bachelez H, VernantJP,  Dreyfus F, Hermine O. Traitement des leucémies /lymphomes T deladulte (ATL) associées au rétrovirus HTLV1 par une combinaison dAZT etdinterféron alpha. Groupe détude des lymphomes de ladulte, Annecy,France 1995. 1994 Bazarbachi A, Saal F, Laroche L, Capesius C, Flageul B, Peries J, de Thé H.HTLV-I provirus and mycosis fungoides. VI International conference on humanretrovirology: HTLV. Atlantic City, USA, 1994.  Aids. Res. Hum.Retrovirus. 1994, 10: 475. Bazarbachi A, Saal F, Peries J, de Thé H. No evidenceof HTLV-I infection markers in mycosis fungoides and sezary syndrome as seen inFrance. American Society of Hematology, Nashville, USA 1994. Blood,1994, 84 (suppl 1): 478a. 1990-1991 Bazarbachi A, Scobohaci ML, Gisselbrecht C, Drouet L. Why venoocclusive diseaseis less frequent in autologous Bone Marrow Transplantation.  AmericanSociety of Hematology, BOSTON,  USA 1990. Blood, 1990, 76(supplt 1). Bazarbachi A, Saal F, Lasneret J, Laroche L, Galibert F, Peries J, Daniel MT.HTLVI like virus  in a patient with sezary syndrome. IV InternationalConference on human retrovirology,  Montego-Bay, Jamaica 1991. Bazarbachi A, Hojman F, Saal F, Lasneret J, Gout O, Peries J. Detection of HTLVIunintegrated  DNA in cell lines and PBL of ATL and TSP patients. IVInternational Conference on human retrovirology,  Montego-Bay ,Jamaica 1991. Bazarbachi A, Scrobohaci ML., Gisselbrecht C, Gluckmann E, Drouet L. Pourquoi lamaladie veino- occlusive est moins fréquente dans lautogreffe de moelle quedans lallogreffe?.  French Society of hematology, Lyon, France1991.POST-DOCTORALFELLOWS,  PH.D. STUDENTS AND M.S. STUDENTS 1-Post doctoral fellows RaghidaAbou MerhiEndothelialcell angiogenesis associated with adult T-cell leukemia and the role of gapjunction communication between leukemic cells and endothelial cells ordendritic cells2000-2004 EvaHamadehEffectof arsenic trioxide alone or in combination on cyclooxygenase activity andprostaglandin production in acute promyelocytic leukemia and adult T cellleukemia2002-2003 RimaHamdanInSitu Tissue Engineering: effect of acellular organ derived extracts on tissue specificdifferentiation of bone marrow derived mesenchymal and hematopoietic stemcells.2005-2009 KazemZibaraEffectof acellular bone marrow extracts on xenografts of hematopoietic stem cells inimmunocompromized mice2007-2009 HibaEl HajjDesignof new targeted therapies for HTLV-I associated adult T-cell leukemia/lymphomausing SCID mice infected with lymphoma spleen cells from mice transgenic forthe Tax gene of HTLV- I2006-2009 2-Co-director of Ph.D. Thesis RihabNasrPhDThesis, University of Paris VIITherapeutictargeting of Tax and the NF-kB pathway in HTLV-Iassociated Adult T Cell LeukemiaGraduate:April 2005 GeorgesMoarbesPhDThesis, University of Montpellier IEffect and mechanism of action ofEAPB0203, a member of the imidazoquinoxaline family, on T cell lymphomas andHTLV-I associated adult T-cell leukemia/lymphomaGraduate:March 2008 LaraHaddaPhDThesis, University of MarseillesKSHVTransformed Primary Effusion Lymphoma Cells Induce a VEGF dependentAngiogenesis and Establish Functional Gap Junctions with Endothelial Cells.Graduate:October 2008 YoumnaKfouryPhDThesis, University of Paris VIIMolecularmechanisms of Tax induced NF-kB activation.Expecteddate of graduation:December 2009 3- Co-advisor of M.S. Thesis HumamKadara  M.S. Thesis, American Universityof BeirutMechanismsof HPR-induced cell death in HTLV-I transformed cells and malignant T-cellsGraduate:Summer 2003 Roa H. HarbM.S. Thesis, American University of BeirutInterplay between paracrine signaling and direct cell-cellcommunication in tumor cell extravasation.  Graduate: Summer 2004 Ghada Abou-Lteif  M.S. Thesis, American Universityof BeirutRoleof reactive oxygen species in N-(4-hydroxyphenyl)retinamide-induced cell deathin HTLV-I-transformed and malignant T cellsGraduate:Fall 2008 Ansam Sinjab  M.S. Thesis, American Universityof BeirutMechanism of Action of theMammalian Target of Rapamycin (mTOR) Inhibitor in T-cell Lymphomas and HTLV-1 AssociatedAdult T-cell Leukemia/LymphomaExpected date of graduation:Summer 2009 Georgette Francis  M.S. Thesis, American Universityof BeirutN-(4-hydroxyphenyl)retinamideon HTLV-I associated Adult T-cell Leukemia/Lymphoma using SCID mice Infectedwith lymphoma cells from mice transgenic for the Tax gene of HTLV- I Expected date of graduation:Summer 2009  4-Membership of M.S. thesis committee Hayfa BeylumM.S. Thesis, American University of BeirutAssociation of altered T cell immunity with insulin - dependentdiabetes mellitusGraduate: Summer 1997 Nour AbboushiM.S. Thesis, American University of BeirutCeramide inhibits interleukin-2-inductionGraduate: Fall 1998 Asma Hatoum M.S. Thesis, AmericanUniversity of BeirutMolecular mechanisms of cell cycle control in retinoic acid receptorgamma-transduced neoplastic epidermal cell lines Graduate: Fall 2000 Maria MaaloufM.S. Thesis, American University of BeirutModulation of cell death and the ceramide response by adenovirus. Graduate: Fall 2000 HishamBazziM.S. Thesis, American Universityof BeirutEffectof ultraviolet radiation on retinoid and activator protein-1 signaling inprimary keratinocytes and its modulation by retinoidsGraduate:Summer 2001 MohammadKabbout  M.S. Thesis, American Universityof BeirutRegulationof neoplastic keratinocyte proliferation and cell cycle control by thesynthetic retinoid N-(4-hydroxyphenyl)retinamideGraduate:Summer 2002 SaraEl-Banna  M.S. Thesis, American University of BeirutMolecularbasis of the antineoplastic effects of components of Lebanese sage essentialoil Graduate: Spring 2006 Hilda El-KhouryOrganderived matrix extracts induce organ specific differentiation of human bonemarrow-derived mesenchymal stem cells in vitro.Graduation:Summer 2006 RonyRayes  M.S. Thesis, American Universityof BeirutParacrinestimulation of endothelial cells by leukemic cells: Changes in gene expressionprofileGraduate:Summer 2006 Amani MakkoukM.S. Thesis, American University of BeirutTLR4 agonists as adjuvants in cancer chemotherapy: use ofmonophosphoryl lipid A (MPLA) with Dacarbazine in a murine melanoma model. Graduate: Summer 2008    MirellaBou ChedidM.S. Thesis, American University of BeirutGallotannininhibits the human tumor necrosis factor alpha-induced activation ofNuclear factor kappa B and reduces tumor growth in a mouse xenograft model ofhuman colon cancerGraduate:Summer 2008 SallyDeebM.S. Thesis, American University of BeirutEnhancementof apoptosis by Linalyl Acetate and α-Terpineolthrough targeting the Nuclear Factor-κBactivation Pathway in human colon cancer cells.Expecteddate of graduation: Summer 2009   
This document is to inform dissemination for purpose only, do not represent the views and positions this identity, and identification of the all the facts.
...... Useful
CURRICULUM VITAE

html   Quick View
←APLASTIC ANAEMIA 2000; 07→
Related Latest Updates
    •  IRON DEFICIENCYdoc (2003)var pp = "242&pre="+(new Date()).getTime(); var s=String(window.location.href); var host=escape(s.substring(7,s.indexOf(...
    •  Supplementary Table 6TableS1. Hypothalamicvalidation PCR primer sequences employed.  > Gene Target Forward primer Reverrse primer Product...
    •  Diseases of the BLOODDiseases of the BLOODEmelita M. Gatmaitan, MD, FPPS PediatricsThe AnemiasDefinition: A reduction of the RBC volume or Hgb conc....
    •  2000; 07Haematologica vol. 85(7):July 2000Red Cells & IronABSTRACTCongenital dyserythropoietic anemia type III HERBERT SANDSTRÖM,* AND...
    •  CURRICULUM VITAECURRICULUM VITAEAli A. Bazarbachi, M.D., Ph.D. Date of Birth:  January 25, 1965.Address:  Department of Internal Medicine...